IMAGE

Figure 5

ID: ZDB-IMAGE-191230-936
Publication: Cheng et al., 2019 - Ciglitazone-a human PPARγ agonist-disrupts dorsoventral patterning in zebrafish
All Figures: Figures for Cheng et al., 2019

Image

Figure Caption

Figure 5 DMP reverses the ventralizing effects of ciglitazone.

Mean (+standard deviation) percent of normal, ventralized, dorsalized, delayed, or dead embryos following exposure to vehicle (0.2% DMSO), 0.078 µM DMP, 12.5 µM ciglitazone (Cig), or 0.078 µM DMP + 12.5 µM Cig (N = 60 embryos per treatment) (A). Asterisk (*) denotes a significant difference (p < 0.05) in the percent of normal embryos relative to vehicle (0.2% DMSO) controls. Representative images of embryos following exposure to vehicle (0.2% DMSO), 0.078 µM DMP, 12.5 µM ciglitazone, or 0.078 µM DMP + 12.5 µM Cig (B–E). Immunostaining with anti-phosphoSMAD-1/5/9 within 8-hpf embryos following exposure to vehicle (0.2% DMSO), 0.078 µM DMP, 12.5 µM Cig, or 0.078 µM DMP + 12.5 µM Cig; embryos exposed to 0.625 µM DMP were included as a positive control for disruption of BMP signaling gradients. Arrowheads point to elevated pSMAD 1/5/9 staining on the ventral side of the embryo (F–J).

Figure Data

Phenotype details

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Peer J.